In pre-clinical trials, Darcy et al. examined self-antigen human epidermal growth factor receptor 2 (Her2) in transgenic mice and used two different Her2+ tumor targets to investigate anti-tumor efficacy and safety of CAR T cells and anti-PD-1 antibody in the combined form [148]. The gene discussed is PDCD1; the disease is neoplasm.